Effects of Oral Dydrogesterone and Oral Medroxyprogesterone Acetate in the Treatment of Abnormal Uterine Bleeding-Ovulatory Dysfunction in ReproductiveAged Women from 18 to 39 years old: A Five-Year Chart Review / [author]: Palabrica, Nicolette Vanesa L. [co-author]: Reyes, Lylah D.

Contributor(s):

Language: English Publication details: Fairview, Quezon City: Department of OBgyne, FEU-NRMF, 2023Description: ( in folder) with flash drive (soft copy)Content type:

text

Media type:

unmediated

Carrier type:

volume

LOC classification:

OB 2023 0006

Summary: ABSTRACT: Background: Anovulatory cycles possess an estrogenic endometrium with absence of progesterone to regulate and organize the endometrium. Hence, one treatment approach for ovulatory dysfunction is the use of progestins to have a scheduled and well-ordered withdrawal bleeding. Objective: Compare the effects of oral dydrogesterone and oral medroxyprogesterone acetate in the treatment of abnormal uterine bleeding-ovulatory dysfunction among reproductive aged women from 18 to 39 years from 2016 to 2020. Methods: A five-year retrospective cohort which reviewed charts of women with abnormal uterine bleeding-ovulatory dysfunction who were either given oral dydrogesterone or medroxyprogesterone acetate. Data extracted were patient’s age, gravidity, parity, progesterone agent used, menstrual cycle regularity, frequency of menses, duration of menses, menstrual blood loss score and its adverse effects. Purposive Sampling done. Chi-square and t-test were used to compare the effects of the two progestins. Result: Eligible for review were 310 charts of women who received oral progestin with 155 cases for each arm. After the 6-month treatment, Dydrogesterone and Medroxyprogesterone acetate both resulted to regular, as well as normal menstrual cycle frequency, duration of menses, and menstrual blood loss (p < 0.05). Their effect on mean frequency, cycle variation, duration, and blood loss volume were comparable.Reported adverse effects were also similar, 46.5% (87) for those with Dydrogesterone and 53.4% (100) with Oral Medroxyprogesterone acetate (p 0.31). Conclusion: Oral Dydrogesterone and Oral Medroxyprogesterone Acetate when used for treatment of AUB-0 have comparable effects on the menstrual parameters and reported adverse effects. Keywords: Abnormal Uterine Bleeding, AUB-O, Ovulatory Dysfunction, Oral Medroxyprogesterone Acetate, Oral Dyrogesterone

Average rating: 0.0 (0 votes)

Holdings
Item type	Current library	Call number	Status	Date due	Barcode
Room Use	Far Eastern University - Nicanor Reyes Medical Foundation	OB 2023 0006 (Browse shelf(Opens below))	Available		R000760

Browsing Far Eastern University - Nicanor Reyes Medical Foundation shelves Close shelf browser (Hides shelf browser)

Previous	No cover image available	No cover image available	No cover image available	No cover image available	No cover image available	No cover image available	No cover image available	Next
Previous	OB 2023 0003 Factors affecting the turnaround time at the emergency room for obstetrics and gynecology patients in a tertiary hospital in Fairview, Quezon city. / [principal investigator]: Lopez-Caritativo, Amier Dayle A.	OB 2023 0004 Association of factors with the use of oxytocin combined with other uterotonics versus oxytocin alone in the prevention of primary postpartum hemorrhage in a tertiary medical center from 2016 to 2019. / [principal investigator]: Dosado, Odessa L. [co-author]: Reyes, Lylah D.	OB 2023 0005 Pregnancy outcomes of Subchorionic Hemorrhage during the 1st trimester among women with uncomplicated pregnancies seen at a Tertiary Medical Center from 2018 to 2021. / [principal investigator]: Chin, Ayessa A. [co-author]: Reyes, Lylah D.	OB 2023 0006 Effects of Oral Dydrogesterone and Oral Medroxyprogesterone Acetate in the Treatment of Abnormal Uterine Bleeding-Ovulatory Dysfunction in ReproductiveAged Women from 18 to 39 years old: A Five-Year Chart Review / [author]: Palabrica, Nicolette Vanesa L. [co-author]: Reyes, Lylah D.	OB 2024 0001 One big transition: three cases of malignant transformation of mature cystic teratoma / [author]: Popen-Rono, Onelth Dec A. [co-authors]: Castro, Abigail Elsie DG., Duenas, Rommel Z.	OB 2024 0002 Lost implantation: a case report of ovarian pregnancy after ovulation induction and artificial insemination / [author]: Garduce, Maiden M. [co-author]: Enriquez-Gamboa , Michelle	OB 2024 0002 Heavy eye syndrome: a case report / [author]: Puertollano Punzalan, Ellore Noelle, Barja, Claire Baldovino	Next

Includes bibliographical references.

ABSTRACT:
Background: Anovulatory cycles possess an estrogenic endometrium with absence of progesterone to regulate and organize the endometrium. Hence, one treatment approach for ovulatory dysfunction is the use of progestins to have a scheduled and well-ordered withdrawal bleeding.
Objective: Compare the effects of oral dydrogesterone and oral medroxyprogesterone acetate in the treatment of abnormal uterine bleeding-ovulatory dysfunction among reproductive aged women from 18 to 39 years from 2016 to 2020.
Methods: A five-year retrospective cohort which reviewed charts of women with abnormal uterine bleeding-ovulatory dysfunction who were either given oral dydrogesterone or medroxyprogesterone acetate. Data extracted were patient’s age, gravidity, parity, progesterone agent used, menstrual cycle regularity, frequency of menses, duration of menses, menstrual blood loss score and its adverse effects. Purposive Sampling done. Chi-square and t-test were used to compare the effects of the two progestins.
Result: Eligible for review were 310 charts of women who received oral progestin with 155 cases for each arm. After the 6-month treatment, Dydrogesterone and Medroxyprogesterone acetate both resulted to regular, as well as normal menstrual cycle frequency, duration of menses, and menstrual blood loss (p < 0.05). Their effect on mean frequency, cycle variation, duration, and blood loss volume were comparable.Reported adverse effects were also similar, 46.5% (87) for those with Dydrogesterone and 53.4% (100) with Oral Medroxyprogesterone acetate (p 0.31).
Conclusion: Oral Dydrogesterone and Oral Medroxyprogesterone Acetate when used for
treatment of AUB-0 have comparable effects on the menstrual parameters and reported
adverse effects.
Keywords: Abnormal Uterine Bleeding, AUB-O, Ovulatory Dysfunction, Oral
Medroxyprogesterone Acetate, Oral Dyrogesterone

Department of Obstetrics & Gynecology Research - Department of Obstetrics & Gynecology

There are no comments on this title.

to post a comment.